{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2018"],"condition":["Colorectal cancer, Gastric cancer, Esophageal cancer, Biliary tract cancer, Pancreatic cancer, and Other gastrointestinal cancer"],"disease":["Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Biliary Tract Cancer, Pancreatic Cancer, And Other Gastrointestinal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2648298"],"location":["Japan"],"study_start_month":["9"],"repository":["ECRIN MDR"],"study_status":["Active, not recruiting"],"additional_accession":[]},"is_claimable":false,"name":"A multicenter phase II study of Nivolumab monotherapy in recurrent and/or metastatic gastrointestinal cancer patients with high Tumor Mutation Burden (TMB-H)","description":"Interventions: Monotherapy with Nivolumab 360 mg, every 3 weeks intravenous administration\nPrimary outcome(s): Objective response rate (ORR) determined by RECIST v1.1\nStudy Design: Single arm Non-randomized","dates":{"creation":"2018-09-15"},"accession":"2648298","cross_references":{"Japan Primary Registries Network":["JPRN-UMIN000033182"]}}